TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00824499

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Complex regional intervention
Description: Components of the complex intervention:~* Introduction of a program coordinator~* Introduction of a self-management education program~* Bottom up development of a interdisciplinary care protocol~* Support program for the intiation of insulin therapy in primary care~* Regional audit
Study: NCT00403117

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo + Inactive Marijuana (0% THC)
Description: One capsule containing placebo was administered to the participant in a size 00 opaque capsules with lactose filler 45 minutes before marijuana administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo + Active Marijuana (3.27% THC)
Description: One capsule containing placebo was administered to the participant in a size 00 opaque capsules with lactose filler 45 minutes before administration of a marijuana cigarette containing 3.27% THC (ca. 800 mg) provided by the National Institute on Drug Abuse.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone 12 Mg+ Active Marijuana (3.27% THC)
Description: One capsule containing 12mg Naltrexone was administered to the participant in a size 00 opaque capsules with lactose filler 45 minutes before active marijuana administration.
Study: NCT03972696

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Irradiation
Description: BA3S versus BA2 irradiation of lymphatic node areas, administered using a lineal accelerator, after 3D delimitation of the supraclavicular and axillary levels I, II and III. In both treatment arms, further tumoral bed boost will be allowed according to the investigator criteria, whether dose contribution to the nodal areas can be calculated. Due to its nature, interventions cannot be asked.
Study: NCT03010605

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Measuring Every Day Device

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical Therapy
Study: NCT03058107

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutrition Therapy
Description: At the time of diagnosis, patients will immediately be screened and started with Nutrition Therapy if assigned to group A. This regimen will stay in place for 6 weeks to 3 months, after which a switch will be made towards normal dietary counselling. Nutrition Therapy can be given orally, parenterally or via tube feeding (enteral nutrition), depending on the patient's status and aims at matching Caloric Intake with Resting Energy Expenditure. Moreover, a switch between these modalities is possible. Afterwards, standard dietary counselling will be given during the remainder of the study. Follow-up will last one year. If 6 months after the last enrolment the study shows a large difference with the control group, the study will be stopped for ethical reasons.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Control Therapy
Description: At the time of diagnosis, patients will immediately be screened and started with standard dietary counselling for 1 year if assigned to group B. Dietary intervention can be orally, parenterally or via tube feeding (enteral nutrition), depending on the patient's status. Moreover, a switch between these modalities is possible. Follow-up will last 1 year. If 6 months after the last enrolment the study shows a large difference with the control group, the study will be stopped for ethical reasons.
Study: NCT02108639

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DCV 3DAA FDC
Study: NCT00403117

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone 25 Mg + Active Marijuana (3.27% THC)
Description: One capsule containing 12mg Naltrexone was administered to the participant in a size 00 opaque capsules with lactose filler 45 minutes before active marijuana administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone 50 Mg+ Active Marijuana (3.27% THC)
Description: One capsule containing 25mg Naltrexone was administered to the participant in a size 00 opaque capsules with lactose filler 45 minutes before marijuana administration.
Study: NCT03813797

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Airseal®
Description: Medical device set to the mode Airseal®, pressure adjustment between 5 and 7 mmHg

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Insufflation
Description: Medical device set to the mode Standard Insufflation, pressure adjustment between 12 and 15 mmHg
Study: NCT02448680

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Coagulation FVIIa (Recombinant)
Description: A cross over design to assess the efficacy of 2 separate dose regimens (75 µg/kg and 225 µg/kg) of Coagulation Factor VIIa (Recombinant) for the treatment of bleeding episodes in hemophilia A or B patients with inhibitors to Factor VIII or Factor IX

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Coagulation FVIIa (Recombinant)
Description: A cross over design to assess the efficacy of 2 separate dose regimens (75 µg/kg and 225 µg/kg) of Coagulation Factor VIIa (Recombinant) for the treatment of bleeding episodes in hemophilia A or B patients with inhibitors to Factor VIII or Factor IX
Study: NCT02108639

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-791325
Study: NCT02195401

Intervention type: OTHER
Intervention: Cleanroom
Description: Cleanroom with air the quality of the pre-industrial age
Study: NCT02195544

Intervention type: DRUG
Intervention: Synvisc®
Study: NCT01460628

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Armodafinil
Description: Women who are eligible will receive 4 weeks of treatment with armodafinil. Armodafinil will be titrated from 50-mg/day up to 150-mg/day. For exploratory reasons only, at the end of the 4-week treatment period, participants will enter a discontinuation phase in which they will be randomized to double-blind treatment with armodafinil 150-mg/day or matching placebo for 2 weeks in a 1-to-1 ratio. No primary outcomes were studied in the discontinuation phase.
Study: NCT03435640

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NKTR-262
Description: During Phase 1 Doublet: Patients receive escalating doses of NKTR-262 IT (starting dose 0.03 mg) in 3-week treatment cycles. During Phase 1 Doublet (Cohort A), Phase 2 Doublet: Patients were to receive the RP2D of NKTR-262.~During Phase 1 Triplet (Cohort B), and Phase 2 Triplet: Patients receive the RP2D of NKTR-262.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bempegaldesleukin
Description: During Phase 1 Doublet (Cohort A), and proposed Phase 2 Doublet: Patients receive 0.006 mg/kg bempegaldesleukin administered in 3-week treatment cycles.~During Phase 1 Triplet (Cohort B), and proposed Phase 2 Triplet: Patients receive 0.006 mg/kg bempegaldesleukin administered in 3-week treatment cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nivolumab
Description: During Phase 1 Triplet (Cohort B), and proposed Phase 2 Triplet: Patients receive a nivolumab flat dose of 360 mg administered in 3-week treatment cycles.
Study: NCT00015938

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vinorelbine
Study: NCT00570479

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: anecortave acetate
Description: Patients will receive the specified dose of anecortave acetate every 4 months in an anterior juxtascleral depot injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: anecortave acetate
Description: Patients will receive the specified dose of anecortave acetate every 4 months in an anterior juxtascleral depot injection
Study: NCT00403117

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone 100 Mg+ Active Marijuana (3.27% THC)
Description: One capsule containing 50mg Naltrexone was administered to the participant in a size 00 opaque capsules with lactose filler 45 minutes before marijuana administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone 12 Mg + Inactive Marijuana (0% THC)
Description: One capsule containing 12mg Naltrexone was administered to the participant in a size 00 opaque capsules with lactose filler 45 minutes before inactive marijuana administration.
Study: NCT03163264

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer Assisted Lifestyle
Description: Patients will use PAL online tool accessing weight management and lifestyle behaviors, and will meet with a health coach regularly to establish SMART goals.
Study: NCT00403117

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone 25 Mg + Inactive Marijuana (0% THC)
Description: One capsule containing 25mg Naltrexone was administered to the participant in a size 00 opaque capsules with lactose filler 45 minutes before inactive marijuana administration.
Study: NCT03163264

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Usual Care
Description: Patients will be given information on healthy living messages that were created by the VA, and given more information on specific messages they are interested in from the health coaches, but will not receive official coaching. These messages are the current standard of care at the VA for obesity counseling.
Study: NCT00403117

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone 50 Mg + Inactive Marijuana (0% THC)
Description: One capsule containing 50mg Naltrexone was administered to the participant in a size 00 opaque capsules with lactose filler 45 minutes before inactive marijuana administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone 100 Mg + Inactive Marijuana (0% THC)
Description: One capsule containing 100mg Naltrexone was administered to the participant in a size 00 opaque capsules with lactose filler 45 minutes before inactive marijuana administration.
Study: NCT04451642

Intervention type: PROCEDURE
Intervention: Peripheral nerve block
Description: Peripheral nerve block consists of the administration of a local anaesthetic into the nerves to inhibit nerve transmission in a specific part of the body. Ultrasound or Nerve stimulator could be used to locate the peripheral nerve. A needle is placed through the anatomical references to administer local anaesthetic around the peripheral nerve. Single-shot or continuous blocks are performed preoperatively and postoperatively as current practice in the surgery theatre. Using ultrasound, in-plane or out-plane approach could be performed. Peripheral nerve block provides excellent intraoperative and postoperative analgesia decreasing the need for intravenous pain drugs. Interscalene block, supraclavicular block, safene block, femoral block, BRILMA block are different kinds of peripheral nerve block using in the anaesthestic current practice.
Study: NCT01381887

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Treatment A: Form=capsule, route=oral administration. Capsule is taken once daily on Day 1 and Day 2 in 1 of 4 treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin 300mg/Placebo
Description: Treatment B: Type=1, unit=mg, number=300, form=capsule, route=oral use. Capsule is taken once on Day 1 in 1 of 4 treatment periods.~Form=capsule, route=oral administration. Capsule is taken once on Day 2 in 1 of 4 treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin 300mg/Canagliflozin 150mg
Description: Treatment D: Type=1, unit=mg, number=300, form=capsule, route=oral use. Capsule is taken once on Day 1 in 1 of 4 treatment periods.~Type=1, unit=mg, number=150, form=capsule, route=oral use. Capsule is taken once on Day 2 in 1 of 4 treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin 300mg
Description: Treatment C: Type=1, unit=mg, number=300, form=capsule, route=oral use. Capsule is taken once daily on Day 1 and Day 2 in 1 of 4 treatment periods.
Study: NCT03032068

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: At-Home Monitoring
Description: Patient reported outcomes, functional measures such as the maximum attainable range of motion (AROM) and the number of steps taken will be tracked using sensors worn by the patient. The AROM sensor values will be verified with range of motion measurements taken using a goniometer during therapy and MD visits.
Study: NCT01458444

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Non invasive ventilation (VNI)
Description: BIPAP® vision

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non invasive ventilation
Description: OPTIFLOW system
Study: NCT02958761

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: intraarticular injections of platelet lysate
Study: NCT02214212

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bright White Light (BWL)
Description: The device emitting BWL will be placed 24 inches from the participant's face on a pre-measured table. The participant will spend 30 minutes with the eyes open in front of the device. This will occur each morning for 10 days.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Red Light (RL)
Description: The device emitting RL will be placed 24 inches from the participant's face on a pre-measured table. The participant will spend 30 minutes with the eyes open in front of the device. This will occur each morning for 10 days.
Study: NCT00890656

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (CTX)
Description: 300 mg/m\^2 by vein (IV) over 3 hours every 12 hours for 6 doses days 1, 2, 3 of

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: 2 mg by vein (IV) weekly for 3: Days 1, 8, 15

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: 50 mg/m\^2 by vein (IV) over 24 hours
Study: NCT02958761

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hyaluronic acid
Description: intraarticular hyaluronic acid (20 mg/2 mL; Hyalgan, Fidia, Abano Terme, Italy) injections at the same intervals
Study: NCT00890656

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decadron
Description: 80 mg by vein (IV) or by mouth (P.O.) daily days 1-4 and 15-18

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: 10 mcg/kg/day (rounded) by vein (IV) or under the skin (subcutaneously) within 72 ± 48 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX)
Description: 200 mg/m2 by vein (IV) over 2 hours followed by 800 mg/m2 over 22 hours on day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ara-C
Description: 3 gm/m\^2 by vein (IV) over 2 hours every 12 hours for 4 doses on days 2 and 3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegaspargase
Description: 2,500 units/m2 by vein (IV) on day 1 of odd courses and day 5 of even courses
Study: NCT01023737

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: The HCQ study dose levels are defined as 400mg/day, 600mg/day, 800mg/day and 1000mg/day (oral dosing)during the phase I MTD determination. HCQ will be administered starting on Day 2 of Cycle 1 and will be continued daily thereafter until progression of disease or unacceptable toxicity develops.
Study: NCT03641885

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mothers and adolescents
Description: The intervention package will be sent to mothers and adolescents via Telegram social media. It contains behavior change techniques targeting outcome expectancy, self-efficacy, action planning, coping planning, and self-monitoring. There will be 3 assessment points in time, baselines, 1 month and six months after interventions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: adolescents
Description: The intervention package will be sent to only adolescents via Telegram social media. It contains behavior change techniques targeting outcome expectancy, self-efficacy, action planning, coping planning, and self-monitoring. There will be 3 assessment points in time, baselines, 1 month and six months after interventions.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: active control
Description: The active control group receives an information sheet regarding recommendations on oral health behavior via telegram. There will be 3 assessment points in time, with 1 month and six months in between.
Study: NCT04257513

Intervention type: DIAGNOSTIC_TEST
Intervention: Brain MRI
Description: Neurological and Cognitive evaluation; Brain MRI

Intervention type: DIAGNOSTIC_TEST
Intervention: Brain MRI
Description: Neurological and Cognitive evaluation; Brain MRI

Intervention type: DIAGNOSTIC_TEST
Intervention: Brain MRI
Description: Neurological and Cognitive evaluation; Brain MRI
Study: NCT01097681

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP1941
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP1941
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP1941
Description: oral
Study: NCT04389632

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sigvotatug vedotin
Description: Administered into the vein (IV; intravenously)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sigvotatug vedotin
Description: Administered into the vein (IV; intravenously)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sigvotatug vedotin
Description: Administered into the vein (IV; intravenously)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sigvotatug vedotin
Description: Administered into the vein (IV; intravenously)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sigvotatug vedotin
Description: Administered into the vein (IV; intravenously)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: 200mg every 3 weeks or 400mg every 6 weeks, given by IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: 200mg every 3 weeks or 400mg every 6 weeks, given by IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: 200mg every 3 weeks or 400mg every 6 weeks, given by IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: 75 mg/m2 every 3 weeks, given by IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: 75 mg/m2 every 3 weeks, given by IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: AUC 5 mg/mL per min every 3 weeks, given by IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: AUC 5 mg/mL per min every 3 weeks, given by IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: AUC 5 mg/mL per min every 3 weeks, given by IV
Study: NCT01150370

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The PrePex a novel device for adult male circumcision
Description: The PrePex System was designed to enable safe, effective, painless and bloodless male circumcision programs. The PrePex System includes a simple, disposable device that is easy to use and can be deployed by minimally trained healthcare professionals, without the need for sterile, hospital settings.
Study: NCT00674843

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Far Infrared Radiation
Description: Radiation: Far Infrared Radiation (5μm to 20μm wavelength) Far Infrared radiation for 30 to 40 minutes per treatment session.
Study: NCT01444924

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivicaine
Description: The TAP block will be placed using a standardized ultrasound-guided approach. Subjects assigned to the study group will have an injection of 30 mL 0.25% bupivacaine, a local anesthetic with 3 mcg/mL of epinephrine, placed into the plane between the internal oblique and the transversus abdominis

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo block will be placed in a similar manner, using a standardized ultrasound-guided approach. The placebo injection will consist of 30 mL sterile, preservative-free saline.
Study: NCT02016599

Intervention type: OTHER
Intervention: Monitoring and biospecimen collection
Description: The study team will use monitoring methods normally used in the NICU (physical exams, echocardiograms, and ECG) and some new monitoring methods (Near-infrared spectroscopy or NIRS) to find out all the changes that a baby's heart and lungs go through during the first week after delivery. In addition, blood samples will be taken to assess lactate, troponin, and creatinine levels.

Intervention type: OTHER
Intervention: Monitoring and biospecimen collection
Description: The study team will use monitoring methods normally used in the NICU (physical exams, echocardiograms, and ECG) and some new monitoring methods (Near-infrared spectroscopy or NIRS) to find out all the changes that a baby's heart and lungs go through during the first week after delivery. In addition, blood samples will be taken to assess lactate, troponin, and creatinine levels.
Study: NCT04103645

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vactosertib
Description: This drug is a TGF-Beta receptor type 1 inhibitor, by inhibiting phosphorylation of the ALK5 substrates SMAD2 and SMAD3. This inhibition could promote regeneration of normal human stem cells and proliferation of erythroid progenitors to treat the underlying hypoproliferative anemia in advanced MPNs.
Study: NCT04058756

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PDR001
Description: PDR001
Study: NCT03813290

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neuro-technological Intervention
Description: During the intervention sessions, participants will don a head-mounted VR display set and a mobile EEG-biosensor. Each session will begin with a brief audio-guided mindfulness practice, follow by a 15 minutes VR game. Game performances will be influenced by individual's level of anxiety arousal and ability to regulate it.
Study: NCT04274218

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Perturbation
Description: Participants from both cohorts will experience a simulated trip while walking on the treadmill. The trip is induced through a rapid acceleration and deceleration of the treadmill belt speed.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Perturbation
Description: Participants from both cohorts will experience a simulated trip while walking on the treadmill. The trip is induced through a rapid acceleration and deceleration of the treadmill belt speed.
Study: NCT03266627

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytotoxic t-lymphocytes
Description: adenovirus specific cytotoxic t-lymphocytes will be collected and manufactured from HLA matched related or HLA mis-matched related donors and administered to eligible patients with refractory adenovirus or PID.
Study: NCT00642265

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: osteosynthesis
Description: operative treatment

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: sling
Description: conservative treatment
Study: NCT00306098

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: islets
Description: Intraportal infusion of islets
Study: NCT00420056

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-0332991
Description: 125 mg, oral, Days 1-21 of a 28-day cycle